摘要
目的研究免疫调节药胸腺素α1治疗重症肝炎并发自发性细菌性腹膜炎的临床效果。方法50例重症肝炎并发自发性细菌性腹膜炎患者,随机分为两组。对照组29例,给予常规治疗。治疗组21例,在常规治疗基础上,给予胸腺素α11.6mg,sc,qd,14d后改为1周2次。观察两组患者临床指标变化及预后。结果治疗组患者与对照组比较,临床症状与体征有效缓解,实验室指标改善,肝、肾功能恢复,生存率提高。结论胸腺素α1可有效治疗慢性重症肝炎并发自发性细菌性腹膜炎,改善患者预后。
Objective To investigate the clinical effects of thymosin α1 on fulminant hepatitis complicated by spontaneous bacterial peritonitis（SBP）. Methods Fifty cases of fulminant hepatitis complicated by SBP were divided into two groups,the control group （29 cases） with routine treatment, and the treatment group （21 cases）with both routine treatment and thymosin α1. Results Thymosin α1 could effectively relieve the clinical symptoms and signs, improve the laboratory indexes, restore the functions of the liver and kidney with a rise in the patients＇ survival rate. Conclusion Thymosin α1 can effectively cure chronic fulminant hepatitis complicated by SBP with improvement in the patient＇ s prognosis.
出处
《医药导报》
CAS
2006年第7期651-654,共4页
Herald of Medicine
关键词
胸腺素Α1
肝炎
重症
慢性
腹膜炎
细菌性
自发性
Thymosin α1
Chronic fulminant hepatitis
Spontaneous bacterial peritonitis
